The Dutch government has awarded ProQR a 4.7 million euro innovation credit for the development of QR-110, the company’s Leber’s congenital amaurosis 10 treatment candidate, according to a release.
Awarded through the RVO of the Ministry of Economic Affairs, the innovation credit is awarded to companies developing promising innovations, the release said.
ProQR will use the funds to conduct a phase 2/3 study of QR-110, an RNA-based oligonucleotide designed to address the underlying cause of LCA10 in the CEP290 gene, and to obtain regulatory and ethical market approval. Repayment of
Uncategorized